COMPANY PROFILE

ISA Pharmaceuticals

Explore full profile

Developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections

Leiden, NetherlandsFounded 2004Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About ISA Pharmaceuticals

ISA Pharmaceuticals focuses on developing targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. The company operates in the biotechnology sector, primarily serving patients and healthcare providers. ISA Pharmaceuticals' business model revolves around the research, development, and commercialization of immunotherapy treatments. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company is actively involved in clinical trials, such as the Phase II combination trial of its lead immunotherapy ISA101b. ISA Pharmaceuticals also adapts to emerging health crises, as evidenced by its development of ISA106 SLP therapeutic for COVID-19.

MoreLess Source: Dealroom company data

At a glance

Status: Closed
Founded: 2004
Headquarters: Leiden, Netherlands
Employees: 5
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Pay Per Result, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jul 2021	$29M	$114M	Invest-NL · Regeneron Pharmaceuticals	—
DEBT✓Debt	Oct 2019	$22M	—	European Investment Bank	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

ISA Pharmaceuticals website traffic

Latest recorded traffic for ISA Pharmaceuticals is 610 monthly website visits, up 5.2% over the last three months. ISA Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits610 3-month web change+5.2% 1-year team growth0%

Monthly website visitsFeb 2017–Feb 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational	1	$9.7M	$12M
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
COCoridonCoridon develops DNA therapies for the prevention and treatment of viral infections, and therapeutic vaccines for the treatment of cancer	Brand, Austria	Operational
ETEureka TherapeuticsBiotechnology company focuses on an immunotherapies for the treatment of cancer	Emeryville, United States	Operational
DCDCprimeDCprime – We help shape a new era in cancer immunotherapeutics	Leiden, Netherlands	Operational
IPIndex PharmaceuticalsDeveloping drugs to treat inflammatory bowel disease that can help patients return to a normal life	Solna kommun, Sweden	Operational
CPCorvus PharmaceuticalsClinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer	Burlingame, United States	Operational
BPBiosortia PharmaceuticalsBiosortia is working on new drugs from deep access to the chemistry of the microbiome for immuno-oncology & immunological therapeutics	Dublin, United States	Operational